HEM파마

376270KOSDAQ자연과학 및 공학 연구개발업

49.2 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40

News Sentiment17.2 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Declined 9.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HEM Pharma is a global microbiome specialist company offering personalized healthcare services and LBP (Live Biotherapeutic Products) discovery platforms. Utilizing its proprietary PMAS technology, the company simulates microbiome environments to provide customized solutions and collaborates with global pharmaceutical firms and Amway, expanding into markets such as Japan and Vietnam.

Number of Employees

101people

Average Salary

55.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-151.43Industry Average -32.113.5Point

4.7x industry avg (excellent)

Debt Ratio

117.61Industry Average 7.520.0Point

15.6x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲84.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼34.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -82.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 0Negative 1Average Sentiment Score 75

Positive
HEM파마, 피지컬 AI 플랫폼 ‘바이그널’ 상표 출원...구독형 헬스...
HEM파마는 마이크로바이옴 빅데이터와 AI를 결합한 피지컬 AI 플랫폼 '바이그널'의 상표를 출원하며 구독형 디지털 헬스케어 사업에 진출합니다.
Negative
HEM파마, 물적분할 신설법인 설립 계획 철회
HEM파마는 주주총회에서 물적분할 안건이 부결됨에 따라 신설법인 설립 계획을 철회했습니다.
Positive
HEM파마, 올해 예상 영업익 115억원…日 암웨이 매출 잭팟 예고-리...
리딩투자증권은 HEM파마가 일본 암웨이로부터 71억원 규모의 선발주를 받아 올해 115억원의 영업이익을 예상하며 폭발적인 매출 성장을 기대했습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (58%)

Current 62,900Won52-week high 94,00052-week low 18,180

1-month return1.0Point

1m -9.76% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-06
Neutral주식등의대량보유상황보고서(일반)2026-04-06
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral[기재정정]주요사항보고서(회사분할결정)2026-03-27
Neutral기업설명회(IR)개최2026-03-25